MSD wins patent extension feud over post-surgery drug

The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

To cite or not to cite: How can we avoid misuse of AI in court?

4 March 2026 With an increase in ‘hallucinated’ case law cited as evidence in courts globally, what can legal practitioners—as well as providers of AI tools and platforms—do to help safeguard against this? Sarah Speight finds out.

Americas

LSPN Awards 2026 finalists revealed

2 March 2026 Law firms, companies and individuals have been shortlisted across a range of categories, which this year include new awards for excellence in PTAB, trade secrets and medical device work.

Americas

Natera and a rival draw the line under five-year fight

27 February 2026 The companies have agreed to dismiss their long-running patent fight over tumour-informed liquid biopsy technology, closing a high-stakes chapter in the fast-growing MRD testing market—while leaving the door open to future claims.

More features

DWT recruits first-chair trial litigator as latest hire in IP expansion

To cite or not to cite: How can we avoid misuse of AI in court?

Gowling WLG brings in transactions expert with UK and US experience

LSPN Awards 2026 finalists revealed

Natera and a rival draw the line under five-year fight

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling

Eli Lilly escapes $278m payout in biotech licensing dispute

Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices

MSD wins patent extension feud over post-surgery drug

More on this story

Editor's picks

Editor's picks

More features